Piperacillin / Tazobactam Injection — Competitive Intelligence Brief

Piperacillin / Tazobactam Injection (Piperacillin / Tazobactam Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

marketed Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins; bacterial beta-lactamase enzymes Infectious Disease Small molecule

Target snapshot

Piperacillin / Tazobactam Injection (Piperacillin / Tazobactam Injection) — Rambam Health Care Campus. Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing the antibiotic to overcome resistance.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Piperacillin / Tazobactam Injection TARGET	Piperacillin / Tazobactam Injection	Rambam Health Care Campus	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins; bacterial beta-lactamase enzymes
Augmentin (ES)-600	Augmentin (ES)-600	GlaxoSmithKline	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
Imipenem+Relebactam	Imipenem+Relebactam	Wake Forest University Health Sciences	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (imipenem); serine beta-lactamases (relebactam)
standard dose amoxicillin/clavulanate	standard dose amoxicillin/clavulanate	Albany Medical College	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
cefoperazone sodium and sulbactam sodium	cefoperazone sodium and sulbactam sodium	Yung Shin Pharm. Ind. Co., Ltd.	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; beta-lactamases
Ampicillin / sulbactam	Ampicillin / sulbactam	Medical University of Vienna	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
ampicillin/clavulanate	ampicillin/clavulanate	Phoenix Children's Hospital	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class